Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Eiger gets FDA breakthrough therapy designation for HDV drug candidate

Eiger BioPharmaceuticals’ (NASDAQ:EIGR) peginterferon lambda (lambda) received FDA breakthrough therapy designation for the treatment of hepatitis delta virus (HDV) infection. HDV is the most severe form of human viral...

August 21, 2019

Developments

Zenabis in $25-million of additional debt financing; extension and partial conversion of notes

Zenabis Global (TSX:ZENA) signed definitive documentation for $25-million of new senior secured debt financing from R.C. Morris Capital Management. The financing involved amending and restating the debenture...

August 21, 2019

Developments

Cerecor gets FDA fast track designation for CERC-802

Cerecor (NASDAQ:CERC) received FDA fast track designation for CERC-802 for the treatment of mannose-phosphate isomerase deficiency, also known as CDG-1b. CDG-1b is a rare genetic disease that impacts carbohydrate...

August 21, 2019

Markets

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

August 21, 2019

Developments

Outlook Therapeutics completes enrollment in Phase 3 wet AMD trial

Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its Phase 3 clinical trial comparing ONS-5010 to ranibizumab for the treatment of wet age-related macular degeneration (AMD). Administered via...

August 20, 2019

Executive Moves

Axsome Therapeutics names David Marek as CCO

David Marek Axsome Therapeutics (NASDAQ:AXSM) has appointed David Marek as chief commercial officer, effective Aug. 31. Mr. Marek joins Axsome from Amgen (NASDAQ:AMGN), where he was most recently VP and general manager...

August 20, 2019

Developments

Myovant Sciences completes recruitment for Phase 3 endometriosis study

Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...

August 20, 2019

Markets

HCW starts Targovax ASA at buy; PT 19 NOK

H.C. Wainwright initiated coverage of Oslo-based Targovax ASA (OSE:TRVX) with a “buy” rating and price target of 19 NOK. The stock closed at 5.44 NOK on Aug. 19. Analyst Joseph Pantginis writes that Targovax’s lead...

August 20, 2019

Markets

BTIG cuts Synlogic PT to $9 from $22

BTIG reduced its price target for Synlogic (NASDAQ:SYBX) to $9 from $22 after the company discontinued development of SYNB1020, an early-stage clinical product candidate for the treatment of hyperammonemia. The stock...

August 20, 2019

Markets

Brookline starts SCYNEXIS at buy; PT $5

Brookline Capital Markets launched coverage of SCYNEXIS (NASDAQ:SCYX) with a “buy” rating and $5 price target. The stock closed at $1.07 on Aug. 19. Analyst Kumaraguru Raja writes that SCYNEXIS’ lead product candidate...

August 20, 2019

Developments

iBio inks 3D bioprinting agreement with United Therapeutics’ subsidiary, Lung Biotechnology PBC

iBio (NYSE AMERICAN:IBIO) entered into an agreement with Lung Biotechnology, a subsidiary of United Therapeutics (NASDAQ:UTHR), to produce recombinant human collagen (rhCollagen)-based bioink for 3D bioprinted organ...

August 19, 2019

Markets

Analysts start Castle Biosciences at buy and OP with PTs of $25-to-$28

Analysts for SVB Leerink, BTIG and Canaccord Genuity launched coverage of Castle Biosciences (NASDAQ:CSTL), saying the company answers a large unmet need in skin cancer. The stock closed at $20.25 on Aug. 16. SVB...

August 19, 2019

Eiger gets FDA breakthrough therapy designation for HDV drug candidate

Zenabis in $25-million of additional debt financing; extension and partial conversion of notes

Cerecor gets FDA fast track designation for CERC-802

HCW starts INmune Bio at buy; PT $11.50

Axsome Therapeutics names David Marek as CCO

Myovant Sciences completes recruitment for Phase 3 endometriosis study

HCW starts Targovax ASA at buy; PT 19 NOK

BTIG cuts Synlogic PT to $9 from $22

Brookline starts SCYNEXIS at buy; PT $5

iBio inks 3D bioprinting agreement with United Therapeutics’ subsidiary, Lung Biotechnology PBC

Analysts start Castle Biosciences at buy and OP with PTs of $25-to-$28

General

More